Pimecrolimus 1% Cream
Phase 1/2Completed 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Netherton Syndrome
Conditions
Netherton Syndrome
Trial Timeline
Sep 1, 2005 → Mar 1, 2008
NCT ID
NCT00208026About Pimecrolimus 1% Cream
Pimecrolimus 1% Cream is a phase 1/2 stage product being developed by Novartis for Netherton Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT00208026. Target conditions include Netherton Syndrome.
Hype Score Breakdown
Clinical
9
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00208026 | Phase 1/2 | Completed |
| NCT00297037 | Phase 2 | Completed |
Competing Products
8 competing products in Netherton Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| DS-2325a | Daiichi Sankyo | Phase 1/2 | 24 |
| DS-2325a + DS-2325a + Placebo + Placebo | Daiichi Sankyo | Phase 1 | 29 |
| DS-2325a + Placebo | Daiichi Sankyo | Phase 1 | 29 |
| BCX17725 + Placebo | BioCryst Pharmaceuticals | Phase 1 | 30 |
| QRX003-2% Lotion + QRX003-4% Lotion QAM + Vehicle + QRX003-4% Lotion BID | Quoin Pharmaceuticals | Phase 2/3 | 32 |
| QRX003, 4% Lotion | Quoin Pharmaceuticals | Phase 2/3 | 35 |
| QRX003, 4% Lotion | Quoin Pharmaceuticals | Phase 2/3 | 35 |
| ATR12-351 | Azitra | Phase 1 | 26 |